<table>
<thead>
<tr>
<th>Variables</th>
<th>Total (N=92)</th>
<th>Group (fibrosis)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Mean± S.D.</td>
<td>36.41 ± 11.03</td>
<td>35.15 ± 10.42</td>
<td>44.83 ± 11.74</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>19 (20.7%)</td>
<td>17 (21.2%)</td>
<td>2 (16.7%)</td>
</tr>
<tr>
<td>Male</td>
<td>73 (79.3%)</td>
<td>63 (78.8%)</td>
<td>10 (83.3%)</td>
</tr>
<tr>
<td>HBV DNA Mean± S.D.</td>
<td>6426399.64±305</td>
<td>5244005.06±270</td>
<td>14309030.17±49</td>
</tr>
<tr>
<td>HBeAg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>81 (88%)</td>
<td>70 (87.5%)</td>
<td>11 (91.7%)</td>
</tr>
<tr>
<td>Positive</td>
<td>11 (12%)</td>
<td>10 (12.5%)</td>
<td>1 (8.3%)</td>
</tr>
<tr>
<td>Anti-HBe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>25 (27.2%)</td>
<td>23 (28.8%)</td>
<td>2 (16.7%)</td>
</tr>
<tr>
<td>Positive</td>
<td>67 (72.8%)</td>
<td>57 (71.2%)</td>
<td>10 (83.3%)</td>
</tr>
<tr>
<td>ALT (IU/l) Median (IQR)</td>
<td>24.85 (18.93 –41)</td>
<td>24.6 (18.93 –40.5)</td>
<td>38 (16 –47)</td>
</tr>
<tr>
<td>AST (IU/l) Mean± S.D.</td>
<td>27.08 ± 12.09</td>
<td>25.65 ± 10.26</td>
<td>36.63 ± 18.44</td>
</tr>
<tr>
<td>Total bilirubin (mg/dl)</td>
<td>0.74 ± 0.24</td>
<td>0.73 ± 0.24</td>
<td>0.78 ± 0.19</td>
</tr>
<tr>
<td>Prothrombin time (seconds) Mean± S.D.</td>
<td>12.88 ± 1.02</td>
<td>12.85 ± 1.01</td>
<td>13.03 ± 1.08</td>
</tr>
<tr>
<td>INR Mean± S.D.</td>
<td>1.05 ± 0.11</td>
<td>1.04 ± 0.11</td>
<td>1.07 ± 0.1</td>
</tr>
<tr>
<td>HB (g/dl) Mean± S.D.</td>
<td>13.98 ± 1.73</td>
<td>14.08 ± 1.69</td>
<td>13.25 ± 1.83</td>
</tr>
<tr>
<td>Platelets (x1,000/mm³)</td>
<td>227.74 ± 67.45</td>
<td>232.74 ± 64.45</td>
<td>194.42 ± 80.05</td>
</tr>
</tbody>
</table>
Table 2: Liver fibrosis stage and inflammation grade by METAVIR score in studied patients (No. = 92)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Summary statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fibrosis</strong></td>
<td></td>
</tr>
<tr>
<td>F0</td>
<td>6 (6.5%)</td>
</tr>
<tr>
<td>F1</td>
<td>36 (39.1%)</td>
</tr>
<tr>
<td>F2</td>
<td>38 (41.3%)</td>
</tr>
<tr>
<td>F3</td>
<td>4 (4.3%)</td>
</tr>
<tr>
<td>F4</td>
<td>8 (8.7%)</td>
</tr>
<tr>
<td><strong>Inflammation</strong></td>
<td></td>
</tr>
<tr>
<td>A0</td>
<td>4 (4.3%)</td>
</tr>
<tr>
<td>A1</td>
<td>43 (46.8%)</td>
</tr>
<tr>
<td>A2</td>
<td>39 (42.4%)</td>
</tr>
<tr>
<td>A3</td>
<td>6 (6.5%)</td>
</tr>
</tbody>
</table>
Table 3: Relation between ALT level and liver fibrosis and inflammation by METAVIR score

<table>
<thead>
<tr>
<th>METAVIR</th>
<th>Mean ALT</th>
<th>Kruskal Wallis test</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>23.92±12.66</td>
<td>4.819</td>
<td>0.306</td>
</tr>
<tr>
<td>1</td>
<td>25.69±12.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>32.81±18.90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>37.75±12.99</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>38.05±30.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>32.18±21.54</td>
<td>4.828</td>
<td>0.185</td>
</tr>
<tr>
<td>1</td>
<td>33.32±17.97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>25.35±15.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>36.70±24.56</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 4: Comparison between histological changes in cases with normal ALT and cases with high ALT.

<table>
<thead>
<tr>
<th>Histological changes</th>
<th>Group</th>
<th>Normal ALT (N= 67)</th>
<th>ALT &gt;ULN (N= 25)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td>5 (7.4%)</td>
<td>1 (4%)</td>
<td>0.051</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>32 (47.8%)</td>
<td>4 (16%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>23 (34.3%)</td>
<td>15 (60%)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>2 (3%)</td>
<td>2 (8%)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>5 (7.5%)</td>
<td>3 (12%)</td>
<td></td>
</tr>
<tr>
<td>Mild to moderate fibrosis (F0-F1-F2)</td>
<td></td>
<td>60 (89.5%)</td>
<td>20 (80%)</td>
<td>0.297</td>
</tr>
<tr>
<td>Advanced fibrosis (F3-F4)</td>
<td></td>
<td>7 (10.5%)</td>
<td>5 (20%)</td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td></td>
<td></td>
<td></td>
<td>0.015</td>
</tr>
<tr>
<td>0</td>
<td></td>
<td>2 (3%)</td>
<td>2 (8%)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>27 (40.3%)</td>
<td>16 (64%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>35 (52.2%)</td>
<td>4 (16%)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>3 (4.5%)</td>
<td>3 (12%)</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: HBeAg state in cases with normal ALT and cases with high ALT.
<table>
<thead>
<tr>
<th>HBeAg</th>
<th>ALT</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal ALT</td>
<td>High ALT</td>
</tr>
<tr>
<td>Negative</td>
<td>62(92.5%)</td>
<td>19(76%)</td>
</tr>
<tr>
<td>Positive</td>
<td>5(7.5%)</td>
<td>6(24%)</td>
</tr>
</tbody>
</table>